Cationic liposomes for cancer immunotherapy
US10881612B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 19, 2016 |
| Grant date | Jan 5, 2021 |
| Priority date | — |
| Expiry date | Sep 16, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K17/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.